Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019
Kodiak management will provide regulatory updates on the company's "2022 Vision" and announce interim data from its on-going Phase 1b clinical study of KSI-301, as well as other business highlights for the third quarter ended
A live webcast of the presentation will be available on the "Investors & Media" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay following the event.
KSI-301 is an investigational therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (
Kodiak™ is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and including new triplet inhibitors for dry AMD and glaucoma. Kodiak is based in
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding our platform technology and potential therapies, future development plans, clinical and regulatory objectives and the timing thereof, anticipated design of planned clinical trials and our ability to advance our product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties discussed in our filings with the
"Kodiak," "ABC Platform" and the Kodiak logo are registered trademarks or trademarks of
John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, email@example.com